Search results
For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medical breakthroughs to prevent, treat, and cure some of the world’s most vexing conditions and diseases.
Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
Pfizer Canada strives to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines. Our diverse portfolio offers a broad range of benefits and solutions to meet the needs of Canadians.
The Pfizer-BioNTech Comirnaty ® Omicron XBB.1.5 subvariant, monovalent COVID-19 vaccine is approved for people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months has not yet been established.
pfizer-biontech covid-19 vaccine (covid-19 mrna vaccine) On September 16, 2021, Health Canada granted full approval (Notice of Compliance or NOC) for COMIRNATY™. The vaccine was initially authorized for use in Canada under an Interim Order Authorization on December 9, 2020 under the name Pfizer-BioNTech COVID-19 Vaccine.
Pfizer Canada is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. We strive to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines.
Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose ...
Sep 28, 2023 · Health Canada has approved Pfizer's updated vaccine to protect people aged six months and older from COVID-19. Thursday's authorization of the Pfizer-BioNTech Comirnaty vaccine takes aim at...
Jun 25, 2022 · Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios for Omicron neutralizing antibody response ...
Oct 7, 2022 · Health Canada has approved Pfizer's new bivalent COVID-19 vaccine that contains mRNA from both the original SARS-CoV-2 virus and the Omicron BA.4 and BA.5 variants.
